80 related articles for article (PubMed ID: 9134180)
1. Headache, circumoral paresthesia, and facial flushing associated with high-dose carmustine infusion.
Woo MH; Ippoliti C; Bruton J; Mehra R; Champlin R; Przepiorka D
Bone Marrow Transplant; 1997 Apr; 19(8):845-7. PubMed ID: 9134180
[TBL] [Abstract][Full Text] [Related]
2. Outpatient sequential high dose alkylation with stem cell support for patients with advanced breast cancer: a phase I-II study.
Genre D; Viens P; Gravis G; Bertucci F; Cowen D; Novakovitch G; Derméche S; Chabannon C; Oziel-Taieb S; Camerlo J; Houvenaeghel G; Jacquemier J; Maraninchi D
Anticancer Res; 2000; 20(3B):2033-40. PubMed ID: 10928147
[TBL] [Abstract][Full Text] [Related]
3. Idiopathic pneumonia syndrome after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for high-risk breast cancer.
Wong R; Rondon G; Saliba RM; Shannon VR; Giralt SA; Champlin RE; Ueno NT
Bone Marrow Transplant; 2003 Jun; 31(12):1157-63. PubMed ID: 12796796
[TBL] [Abstract][Full Text] [Related]
4. Infusion reactions are common after high-dose carmustine in BEAM chemotherapy and are not reduced by lengthening the time of administration.
Perreault S; Baker J; Medoff E; Pratt K; Foss F; Isufi I; Seropian S; Cooper DL
Support Care Cancer; 2017 Jan; 25(1):205-208. PubMed ID: 27614867
[TBL] [Abstract][Full Text] [Related]
5. High-dose BCNU followed by autologous hematopoietic stem cell transplantation in supratentorial high-grade malignant gliomas: a retrospective analysis of 114 patients.
Durando X; Lemaire JJ; Tortochaux J; Van-Praagh I; Kwiatkowski F; Vincent C; Bailly C; Verrelle P; Irthum B; Chazal J; Bay JO
Bone Marrow Transplant; 2003 Apr; 31(7):559-64. PubMed ID: 12692621
[TBL] [Abstract][Full Text] [Related]
6. Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin's disease.
Reece DE; Nevill TJ; Sayegh A; Spinelli JJ; Brockington DA; Barnett MJ; Klingemann HG; Connors JM; Nantel SH; Shepherd JD; Sutherland HJ; Voss NJ; Fairey RN; O'Reilly SE; Phillips GL
Bone Marrow Transplant; 1999 Jun; 23(11):1131-8. PubMed ID: 10382952
[TBL] [Abstract][Full Text] [Related]
7. Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma.
Costa LJ; Micallef IN; Inwards DJ; Johnston PB; Porrata LF; Litzow MR; Ansell SM
Br J Haematol; 2008 Oct; 143(2):268-73. PubMed ID: 18699848
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial of amifostine and carmustine-containing chemotherapy to assess lung-protective effects.
Jones RB; Stockerl-Goldstein KE; Klein J; Murphy J; Blume KG; Dansey R; Martinez C; Matthes S; Nieto Y
Biol Blood Marrow Transplant; 2004 Apr; 10(4):276-82. PubMed ID: 15077226
[TBL] [Abstract][Full Text] [Related]
9. Carmustine infusion reactions are more common with rapid administration.
Janson B; Van Koeverden P; Yip SW; Thakerar A; Mellor JD
Support Care Cancer; 2012 Oct; 20(10):2531-5. PubMed ID: 22252549
[TBL] [Abstract][Full Text] [Related]
10. A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma.
Zimmerman TM; Grinblatt DL; Malloy R; Williams SF
Cancer; 1998 Oct; 83(8):1540-5. PubMed ID: 9781947
[TBL] [Abstract][Full Text] [Related]
11. The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy.
Cheng YC; Rondón G; Yang Y; Smith TL; Gajewski JL; Donato ML; Shpall EJ; Jones R; Hortobagyi GN; Champlin RE; Ueno NT
Biol Blood Marrow Transplant; 2004 Nov; 10(11):794-804. PubMed ID: 15505610
[TBL] [Abstract][Full Text] [Related]
12. Acute coronary syndrome upon receiving carmustine infusion before autologous stem-cell transplantation.
Waibel Pachinger C; Rosselet A; Berthouzoz S; Luthi F; Ketterer N
Hematol Oncol; 2012 Dec; 30(4):216-8. PubMed ID: 22287477
[No Abstract] [Full Text] [Related]
13. High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma.
Wang EH; Chen YA; Corringham S; Bashey A; Holman P; Ball ED; Carrier E
Bone Marrow Transplant; 2004 Oct; 34(7):581-7. PubMed ID: 15273714
[TBL] [Abstract][Full Text] [Related]
14. Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications.
Steingrimsdottir H; Gruber A; Björkholm M; Svensson A; Hansson M
Haematologica; 2000 Aug; 85(8):832-8. PubMed ID: 10942930
[TBL] [Abstract][Full Text] [Related]
15. Limitations of oral busulfan in preparative regimen before hematopoietic stem-cell transplantation.
Kami M; Hamaki T; Maruta Y; Miyakoshi S; Mutou Y
Haematologica; 2002 Feb; 87(2):ELT10. PubMed ID: 11836187
[No Abstract] [Full Text] [Related]
16. [Combination of high-dose chemotherapy with autologous hematopoietic stem cell transplantation for recurrent and high-risk breast cancer: a pilot study].
Shi Y; Pan F; Han X
Zhonghua Yi Xue Za Zhi; 1999 Dec; 79(12):890-3. PubMed ID: 11715500
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies.
Alessandrino EP; Bernasconi P; Colombo A; Caldera D; Martinelli G; Vitulo P; Malcovati L; Nascimbene C; Varettoni M; Volpini E; Klersy C; Bernasconi C
Bone Marrow Transplant; 2000 Feb; 25(3):309-13. PubMed ID: 10673703
[TBL] [Abstract][Full Text] [Related]
18. Cardiac sequelae of doxorubicin and paclitaxel as induction chemotherapy prior to high-dose chemotherapy and peripheral blood progenitor cell transplantation in women with high-risk primary or metastatic breast cancer.
Klein JL; Rey PM; Dansey RD; Karanes C; Du W; Abella E; Cassells L; Hamm C; Peters WP; Baynes RD
Bone Marrow Transplant; 2000 May; 25(10):1047-52. PubMed ID: 10828864
[TBL] [Abstract][Full Text] [Related]
19. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma.
Benekli M; Smiley SL; Younis T; Czuczman MS; Hernandez-Ilizaliturri F; Bambach B; Battiwalla M; Padmanabhan S; McCarthy PL; Hahn T
Bone Marrow Transplant; 2008 Apr; 41(7):613-9. PubMed ID: 18071290
[TBL] [Abstract][Full Text] [Related]
20. [High-dose chemotherapy with autologous peripheral blood stem cell transplantation support in a patient with breast cancer metastasis to bone marrow: immunocytochemical monitoring of cancer-cell contamination].
Uno H; Fujita M; Hino N; Nakagawa H; Miyagawa H; Aoki J; Taniyama K; Sasaki N
Rinsho Ketsueki; 1999 Jul; 40(7):556-62. PubMed ID: 10483138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
